MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 47 Publications

10 Customer Reviews

  • MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

    HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  • HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

     

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

  • JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

    LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

  • Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells MoL1SpVv[3Srb36gRZN{[Xl? NVXH[ZhCOjVizszN NIPPNmhFVVOR MXjJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4yKM7:TR?= NYrYbmJwOjR4OUe0PVY>
HL-60 NXzwOHo6S3m2b4TvfIlkKEG|c3H5 Ml;DOFAh|ryP MoCwOFghcA>? M17oSWROW09? MlHCTWM2ODxzMDFOwG0> NGTIOVYzPDZ7N{S5Oi=>
SMMC-7721 MULDfZRwfG:6aXOgRZN{[Xl? M3L1SVQxKM7:TR?= MW[0PEBp Mnv0SG1UVw>? NH\sTYNKSzVyPUeuNUDPxE1? NFX6PXgzPDZ7N{S5Oi=>
A-549 MljIR5l1d3SxeHnjJGF{e2G7 MVq0NEDPxE1? MV:0PEBp NUPQRXA4TE2VTx?= MYfJR|UxRDFyIN88US=> NHraXJYzPDZ7N{S5Oi=>
MCF-7 M4PNUWN6fG:2b4jpZ{BCe3OjeR?= MnvKOFAh|ryP MVS0PEBp MlrrSG1UVw>? NGPsU4RKSzVyPUeuN{DPxE1? MUWyOFY6PzR7Nh?=
SW-480 MlH1R5l1d3SxeHnjJGF{e2G7 NH2zcoM1OCEQvF2= NXj3NHBrPDhiaB?= NYrB[YM5TE2VTx?= MoHjTWM2OD12IN88US=> NYfrdVY4OjR4OUe0PVY>
NCI-H929 M4XyT2N6fG:2b4jpZ{BCe3OjeR?= M4DSZVEh|ryP NHr3V5o4OiCq M2LIWmROW09? M1nwOWlEPTB;MD6xO{DPxE1? M3znWlI1PjJ3MEi4
293T MVfDfZRwfG:6aXOgRZN{[Xl? M1jKc|ExKM7:TR?= MYm3NkBp NIPzNpJFVVOR MWnJR|UxRDJizszN MX6yOFYzPTB6OB?=
293T MU\GeY5kfGmxbjDBd5NigQ>? NYDLfYZWOTBizszN M3\oRVI1KGh? NX22RoZZTE2VTx?= Ml3KUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? MoPkNlQ3OjVyOEi=
HeLa MYTLbY5ie2ViQYPzZZk> NYHPOYU5OTBizszN NGm4Z|YyKGh? NFL1SYxFVVOR NIHUXG5KdmS3Y3XzJHBCWlBiY3zlZZZi\2ViYomgbY5pcWKrdHnu[{Bxem:|ZXHzc41mKGGldHn2bZR6 NFfZfZMzPDN{MUizNy=>
MDA-MB-231 NV3B[Jh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfXNUDPxE1? NF;vTm84OiCq M{PFRmROW09? NFiwUWJKSzVyPUCuNVgh|ryP MVGyOFE2OzJyNh?=
MCF-7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexJO69VQ>? MlrQO|IhcA>? NWXxWpZ4TE2VTx?= MWHJR|UxRTBwMUOg{txO M361UFI1OTV|MkC2
MCF10A NIm1dVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG3XnQyKM7:TR?= M3nmdFczKGh? M1LNVGROW09? MXXJR|UxRTBwMkmg{txO MYCyOFE2OzJyNh?=
HEK-293 NI\iXndMcW6jc3WgRZN{[Xl? NWP5UlkyOiCjbnSgNlAh|ryP MUOyJIg> MUjEUXNQ MnHrTY5pcWKrdIOgR4hVNUxiYXP0bZZqfHlid3n0bEBKSzVyIH;mJFkhdk1i MVuyN|U1ODd7MB?=
Calu6 NVPKT4NiTnWwY4Tpc44hSXO|YYm= Ml;ENVAh|ryP MV6xPEBp NVrTd2ZGTE2VTx?= M2np[3Nq\26rZnnjZY51dHliYXPjeY12dGG2ZYOg[pJifGG6aX6gdJJm[3W{c3;y MWOyN|UxPjR6Nh?=
IFN-gamma-induced RAW264.7 NW\xfXo4TnWwY4Tpc44hSXO|YYm= NIC0T29FVVOR Ml;hTY5pcWKrdIOgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvODd5IN88US=> M4DkdlIzOjd5Mke3
IPC227F M3H1dmN6fG:2b4jpZ{BCe3OjeR?= NFXGZnIyKM7:TR?= NXf3WmlCPDhiaB?= NHHFT2JFVVOR MYnJR|UxRTBwMEe3JO69VQ>? MYGyNVkzPDV{OB?=
Hepa-1c1c7 NWezXVJyTnWwY4Tpc44hSXO|YYm= NEfTeWwzPSEQvF2= NVjITZF2PiCq NXrm[I5WTE2VTx?= M4LVO2lv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw> M2XaXlIxOzl{NUS0
COS-7 M13OPWN6fG:2b4jpZ{BCe3OjeR?= MXuxNEDPxE1? NXnIUHVoTE2VTx?= MWfJR|UxRDFyIN88US=> M1ny[lE5ODh6MEm3
HuH-7 NHGydnREgXSxdH;4bYMhSXO|YYm= NVLEPFEzOTBizszN MmLkSG1UVw>? M4PtSmlEPTB:MUCg{txO M3LYe|E5ODh6MEm3
OCI-Ly3 Mny1SpVv[3Srb36gRZN{[Xl? NXrUZohvOTBizszNxsA> MmjsOEBp NXzxbJp{TE2VTx?= M4O0b2lv\HWlZYOgbJVu[W5iSXvhdJBiSmGucHjhJJN1[WKrbHn6ZZRqd25id3n0bEBGSzVyIH;mJFEh|ryP NILOPZIyQDB{NEGxNy=>
A2780 cDDP MnjCRZBweHSxc3nzJGF{e2G7 NIj1NowzPCCq NH7SWIlFVVOR MYPJcoR2[2W|IHHwc5B1d3OrczDifUBqdmirYnn0bY5oKFCWRV6g[IVoemGmYYTpc44> Mm[2NVc3QDRyMUi=
LPS-stimulated RAW264.7 cells NFPxdnNHfW6ldHnvckBCe3OjeR?= NFPFZ45FVVOR M{XMc2lvcGmkaYTzJG5HNWujcIDhRkBFVkFiYnnu[Ilv\w>? NGrEXVEyPzRyN{K3Oy=>
PC12 NXXxPJRtTnWwY4Tpc44hSXO|YYm= MkToNVAxKM7:TdMg MnXFNlQhcA>? MmP5SG1UVw>? MmqyTY5pcWKrdIOgOk1QUESDLTDhcoQhUDKRMj3pcoR2[2WmIHP5eI91d3irY3n0fS=> MWOxO|E2QDR3NB?=
PC3 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\LXJEzOCEQvF2= NEXWRYM1QCCq MWnEUXNQ MVPJR|UxRTBwNjFOwG0> MWSxOlY5PjV|Nx?=
LP-1 NGSwfYFCeG:ydH;zbZMhSXO|YYm= NI\abGs{ODBibl2= MlzNNlQhcA>? MVTEUXNQ MXzJcoR2[2W|IHHwc5B1d3OrczDifUBqdmO{ZXHzbY5oKGOuZXH2[YQhWEGUUDDs[ZZmdCCjbnSgdoVlfWOrbnegUYNtNTFicILveIVqdiCuZY\lcC=> M4i0WFE2QTV6NUi5
ES6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEGzNFYh|ryP NVvlcm9GW0GQR1XS
A101D NEn2NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXOSJpKSzVyPUCuNFMzPzlizszN Mm\lV2FPT0WU
OCUB-M MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITHS3JKSzVyPUCuNFM4OzdizszN NWDtTnp[W0GQR1XS
LB2518-MEL M3f2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXoSoI2UUN3ME2wMlA{PzZizszN NX3WbJR7W0GQR1XS
SH-4 NUXqPIZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DSNGlEPTB;MD6wOFMyKM7:TR?= NXXmWVV5W0GQR1XS
KNS-42 M1HQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHkZVVKSzVyPUCuNFQ1PDFizszN MnjpV2FPT0WU
DSH1 NEnrWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXwdYxKSzVyPUCuNFUzQDlizszN NYTtUmNxW0GQR1XS
NTERA-S-cl-D1 M1raVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXKbZRKSzVyPUCuNFU4PzJizszN M2D6bXNCVkeHUh?=
D-542MG MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3p[WtkUUN3ME2wMlA2QTV5IN88US=> M3nobHNCVkeHUh?=
KS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjEW|NnUUN3ME2wMlA3PDV6IN88US=> NIPWc4NUSU6JRWK=
BL-41 MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;MTWM2OD1yLkC2PVQ4KM7:TR?= M4T6THNCVkeHUh?=
LXF-289 NFLYfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMTWM2OD1yLkC3NFY3KM7:TR?= Mn;YV2FPT0WU
D-247MG M4TocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[2VFRKSzVyPUCuNFczODlizszN MoSzV2FPT0WU
MMAC-SF NHvaU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHXUWxKSzVyPUCuNFczPjhizszN NInuSZFUSU6JRWK=
CP66-MEL MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYraR3JtUUN3ME2wMlA4PSEQvF2= M2G0RnNCVkeHUh?=
LB771-HNC MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMEiwN|Yh|ryP NUXkeWpnW0GQR1XS
no-10 NWXXbHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEi5NFkh|ryP NUHYclZVW0GQR1XS
A388 M3f2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEmwOlUh|ryP NILYV4pUSU6JRWK=
OPM-2 NV\zVYlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\NTWM2OD1yLkGwOFc1KM7:TR?= NULOUGQ4W0GQR1XS
OVCAR-4 M{jIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjUTWM2OD1yLkGwPVM5KM7:TR?= MofaV2FPT0WU
HOP-62 NVLBdVFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTPTWM2OD1yLkGwPVQ6KM7:TR?= Mmn6V2FPT0WU
ML-2 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfxTWM2OD1yLkGxPFA3KM7:TR?= MoDIV2FPT0WU
UACC-257 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMUG5Nlch|ryP M4qwZXNCVkeHUh?=
NEC8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\uV2V3UUN3ME2wMlEyQTl3IN88US=> NIH5bVBUSU6JRWK=
ONS-76 M{fucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;xTWM2OD1yLkGyPVM2KM7:TR?= NFTzPFJUSU6JRWK=
KE-37 NWfzTZhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLwTWM2OD1yLkGzNlc5KM7:TR?= NYHRNVdyW0GQR1XS
HT-144 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PFXmlEPTB;MD6xN|g6PSEQvF2= M1L1bXNCVkeHUh?=
LB2241-RCC M4S3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHVTWM2OD1yLkG0NlQ4KM7:TR?= MVrTRW5ITVJ?
TE-5 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvMUZdIUUN3ME2wMlE1Ojd6IN88US=> NY[5WYZTW0GQR1XS
KINGS-1 NYfIW|BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTNTWM2OD1yLkG0O|kh|ryP MoTWV2FPT0WU
NCI-H69 NIrVfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tOWxKSzVyPUCuNVUyPDFizszN M2DQOHNCVkeHUh?=
CAS-1 M2H0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGxXoNDUUN3ME2wMlE2PDh{IN88US=> MVfTRW5ITVJ?
D-263MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jDXmlEPTB;MD6xOlAxPiEQvF2= M3GwW3NCVkeHUh?=
A253 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvRTWM2OD1yLkG2NVI5KM7:TR?= MmfYV2FPT0WU
PF-382 NH7UUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXi5XYRlUUN3ME2wMlE3PzB4IN88US=> NVzDU4RVW0GQR1XS
CESS NHTlWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rJSmlEPTB;MD6xO|A3KM7:TR?= M1e5fXNCVkeHUh?=
MZ2-MEL M{Kx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTzeIRxUUN3ME2wMlE4PTV7IN88US=> NF:1[5VUSU6JRWK=
HEL NFf5XmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XLVWlEPTB;MD6xPFUyPyEQvF2= NELTNY9USU6JRWK=
D-392MG NGrmZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHwTWM2OD1yLkG5NVE2KM7:TR?= MVrTRW5ITVJ?
SK-LMS-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnDSlZKSzVyPUCuNVk{ODNizszN NFfBVYtUSU6JRWK=
GI-ME-N NV;uT5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfVSm5CUUN3ME2wMlE6OzB4IN88US=> NUOwXWlVW0GQR1XS
LB831-BLC M3[3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMUmzOEDPxE1? MUTTRW5ITVJ?
DU-4475 M1[5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;BWWVKSzVyPUCuNVk3PThizszN M3\6fXNCVkeHUh?=
IST-SL1 NFzscGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HG[mlEPTB;MD6yNFA6PCEQvF2= MX;TRW5ITVJ?
GAK NGnB[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHsTWM2OD1yLkKwOVM1KM7:TR?= NIjVVmVUSU6JRWK=
EW-1 M4\OdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[xc25kUUN3ME2wMlIyODR5IN88US=> NH;XXYZUSU6JRWK=
LAMA-84 MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T6ZmlEPTB;MD6yNVg2OSEQvF2= Moe5V2FPT0WU
SK-UT-1 M13rO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrtUYlKSzVyPUCuNlIxPDlizszN MWXTRW5ITVJ?
VA-ES-BJ NXLtTFR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMkKyOVch|ryP NVvXNndTW0GQR1XS
ACN M2XVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHyWpo4UUN3ME2wMlIzPjN6IN88US=> NIrQ[5FUSU6JRWK=
SK-PN-DW MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCcHdKSzVyPUCuNlMyQSEQvF2= MlnPV2FPT0WU
HD-MY-Z MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi3TWM2OD1yLkKzN|A{KM7:TR?= NYfl[4R2W0GQR1XS
LB373-MEL-D M{HMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjMVVVKSzVyPUCuNlQyQThizszN MWHTRW5ITVJ?
COLO-829 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17pZWlEPTB;MD6yOFI2PyEQvF2= MYDTRW5ITVJ?
ES8 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xac2lEPTB;MD6yOFc3OyEQvF2= NYCxUW96W0GQR1XS
RXF393 NXPh[5E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qyS2lEPTB;MD6yOVAyPSEQvF2= NFzkXnZUSU6JRWK=
TK10 NETuW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO4Z21KSzVyPUCuNlU1OzVizszN M2S2[nNCVkeHUh?=
LOUCY MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMkW0OVYh|ryP M1u4THNCVkeHUh?=
MZ7-mel MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[xem9KSzVyPUCuNlY{PzRizszN NVHyRotKW0GQR1XS
CP67-MEL NX76OVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\vTWM2OD1yLkK2O|Mh|ryP NX6zeYZ[W0GQR1XS
C2BBe1 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDINZVKSzVyPUCuNlc6ODdizszN NITjdolUSU6JRWK=
K052 NWDUWm1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMki5PUDPxE1? NEXoWGFUSU6JRWK=
MOLT-16 M2nRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMkm1NlQh|ryP MYLTRW5ITVJ?
KNS-81-FD MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\2[GlEPTB;MD6zNFMzOyEQvF2= M37tZ3NCVkeHUh?=
CMK MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDIS2xKSzVyPUCuN|EyOiEQvF2= MV7TRW5ITVJ?
LAN-6 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwM{GzJO69VQ>? M1\BNHNCVkeHUh?=
KLE M2LGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXTTWM2OD1yLkOxN|A3KM7:TR?= MWDTRW5ITVJ?
NCCIT M1;vdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwM{G3PFMh|ryP NVntOG9FW0GQR1XS
HH MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfpTWM2OD1yLkOyPFk4KM7:TR?= M2rOSXNCVkeHUh?=
TE-8 M3vS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7ofWpiUUN3ME2wMlM1Ojd7IN88US=> MmXrV2FPT0WU
GDM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjMTWM2OD1yLkO1NVA1KM7:TR?= MlmyV2FPT0WU
NCI-H747 M4D6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjUVpVUUUN3ME2wMlM4OTB|IN88US=> NF;BO4ZUSU6JRWK=
NCI-H1092 NYLvUYs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP2TWM2OD1yLkO4PFQ1KM7:TR?= M{LZT3NCVkeHUh?=
8-MG-BA MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHjZ2VKSzVyPUCuN|k5OzdizszN M1yzXXNCVkeHUh?=
NB17 NVPOU2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXC[I9KSzVyPUCuOFI6PyEQvF2= M4XZeHNCVkeHUh?=
LC4-1 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzNJZKSzVyPUCuOFM3ODdizszN Mn7YV2FPT0WU
TE-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwNEWxNVkh|ryP Mmf0V2FPT0WU
KALS-1 M4L1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nVc2lEPTB;MD60OlU5PCEQvF2= NEDsPXpUSU6JRWK=
CCRF-CEM MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNEe2O|Qh|ryP MVrTRW5ITVJ?
OS-RC-2 NFO3U2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\sUXBKSzVyPUCuOFc6PzJizszN Ml\sV2FPT0WU
A704 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\UcYlKSzVyPUCuOFg3QTJizszN NIHTfmxUSU6JRWK=
BB49-HNC NIHpSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPpbIZKSzVyPUCuOFkxQTZizszN MmKwV2FPT0WU
EVSA-T NX7NTGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqXWZKSzVyPUCuOFk6OTFizszN M1i4[nNCVkeHUh?=
Mo-T M1PkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUWyUndQUUN3ME2wMlUyPzZ{IN88US=> NGfaWZdUSU6JRWK=
MONO-MAC-6 M{jPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\PT5VKUUN3ME2wMlU{PjFzIN88US=> NVrKO5ZnW0GQR1XS
BB65-RCC Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NViweGk2UUN3ME2wMlU3QDFzIN88US=> M4TLOXNCVkeHUh?=
NCI-H1882 NUjMSFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHvRYVKSzVyPUCuOVkxOzZizszN MoTZV2FPT0WU
TE-9 NYTVUnkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnxTWM2OD1yLk[xNFM{KM7:TR?= MXvTRW5ITVJ?
NCI-H2126 M3vnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH61SohKSzVyPUCuOlI3PjlizszN NH\KXGZUSU6JRWK=
SF268 NGC1WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXyTWM2OD1yLk[1OlQyKM7:TR?= MkDSV2FPT0WU
SW872 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7F[4JKSzVyPUCuOlU4OjlizszN NXP5NJVtW0GQR1XS
LS-513 M1q5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNk[3OVEh|ryP NImzUZhUSU6JRWK=
NCI-H1355 NHPielZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL0fXJHUUN3ME2wMlY5PjF7IN88US=> MXvTRW5ITVJ?
BL-70 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjqfnlMUUN3ME2wMlY6Ozh6IN88US=> MUDTRW5ITVJ?
NCI-SNU-5 NGXpPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq5XXZGUUN3ME2wMlY6PTR3IN88US=> NXvKOYQzW0GQR1XS
SNU-C2B Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnaR4F[UUN3ME2wMlcxPzN7IN88US=> NGLVNVhUSU6JRWK=
GB-1 NWn3bI16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XLZWlEPTB;MD63NlEzPCEQvF2= M4LCSHNCVkeHUh?=
CTB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHqU|JkUUN3ME2wMlc4QTV3IN88US=> NVXDdmhuW0GQR1XS
Becker NXTmXmg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomxTWM2OD1yLke5OlIyKM7:TR?= M1jGSXNCVkeHUh?=
KM12 NWDuPWx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37YfmlEPTB;MD64OVQ3PiEQvF2= NHz0T5dUSU6JRWK=
ES7 M1PjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\YV4xKSzVyPUCuPFk3PSEQvF2= NEi5b|hUSU6JRWK=
COLO-684 NU\3OoxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jlXGlEPTB;MD65NFY2QCEQvF2= MYnTRW5ITVJ?
HCC2998 NFfyfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfp[Gs2UUN3ME2wMlk{QDV2IN88US=> NGXuTmhUSU6JRWK=
TE-10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT5WlJGUUN3ME2wMlk3PDNizszN MX3TRW5ITVJ?
SF126 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwOUi5O|Eh|ryP MlOyV2FPT0WU
EKVX M2j6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwMEO0OFIh|ryP MnzqV2FPT0WU
KARPAS-45 NUTCPYdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvvbplKUUN3ME2xMlA1ODF4IN88US=> NHrteVhUSU6JRWK=
KGN NXnE[lRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXEeYt7UUN3ME2xMlA2ODR3IN88US=> NYHl[llNW0GQR1XS
ES1 NFjwNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4NmlEPTB;MT6wO|kzOSEQvF2= MnTXV2FPT0WU
L-540 NXKxZVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz2d2Z4UUN3ME2xMlEyQDN7IN88US=> M136V3NCVkeHUh?=
KURAMOCHI NUXxTWFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3sTWM2OD1zLkGyN|c1KM7:TR?= MU\TRW5ITVJ?
LU-65 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\yZ3VKSzVyPUGuNVI4PTNizszN NUnWUWpiW0GQR1XS
MFH-ino MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf0WGNKSzVyPUGuNVc2ODFizszN MVHTRW5ITVJ?
NCI-H23 M2i4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;3bYFKSzVyPUGuNlA1OSEQvF2= NEfTbmlUSU6JRWK=
IA-LM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPWV4pSUUN3ME2xMlI1OTF4IN88US=> M3;PVnNCVkeHUh?=
PSN1 NH;UO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\YN45KSzVyPUGuNlcxOTZizszN Ml20V2FPT0WU
NCI-H719 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyXmlEPTB;MT6yO|QyOSEQvF2= NGLpPHpUSU6JRWK=
SW684 M2TKbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX6TWM2OD1zLkK4OlU6KM7:TR?= MVjTRW5ITVJ?
HCE-4 NU\6doJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwM{CyNlEh|ryP MYnTRW5ITVJ?
EW-16 M1fz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwM{GzOFch|ryP MlLzV2FPT0WU
NCI-H128 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXKTWM2OD1zLkO1PFE1KM7:TR?= MnLQV2FPT0WU
HC-1 M3HpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fieGlEPTB;MT6zPFE4KM7:TR?= M4nNS3NCVkeHUh?=
IST-MES1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXHTWM2OD1zLkSwNlA5KM7:TR?= M3nPVXNCVkeHUh?=
Raji MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nsUWlEPTB;MT60NVg2KM7:TR?= NWfLcI5UW0GQR1XS
DMS-114 NHjobXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwNES1N|kh|ryP MmjMV2FPT0WU
GI-1 M1ew[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TqfmlEPTB;MT60O|E{OSEQvF2= M4[1V3NCVkeHUh?=
NCI-H2081 NIX1VmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwNUWxPVYh|ryP NEmxUIlUSU6JRWK=
LC-1F MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LCNWlEPTB;MT61OVE6QCEQvF2= M1XvXXNCVkeHUh?=
NCI-H2227 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\F[mNTUUN3ME2xMlYyPTZzIN88US=> M1jCW3NCVkeHUh?=
D-502MG NX\QUnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH35OFdKSzVyPUGuOlczOTFizszN MXXTRW5ITVJ?
NCI-H2141 NX62NFBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDL[nBKSzVyPUGuOlc{OTdizszN MXPTRW5ITVJ?
LS-411N NEj4eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwNkm4NFch|ryP MVvTRW5ITVJ?
SU-DHL-1 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[0O|BwUUN3ME2xMlcyOjhzIN88US=> M1H1bXNCVkeHUh?=
BB30-HNC NHT3eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwN{K2PFUh|ryP NWqzW2dtW0GQR1XS
TE-15 NHfpVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rtOmlEPTB;MT65NlM4OyEQvF2= NGXxV4JUSU6JRWK=
JVM-3 NFruWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwOUO5NFQh|ryP MmPkV2FPT0WU
IST-SL2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvYNZBKSzVyPUKuNFEzPTJizszN NIHOclVUSU6JRWK=
EW-18 M1O5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJwMEKzN|ch|ryP MUDTRW5ITVJ?
DJM-1 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwMEK1OVIh|ryP MnTCV2FPT0WU
no-11 MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvuTWM2OD1{LkCzNVA1KM7:TR?= NFTuc|dUSU6JRWK=
QIMR-WIL M2TFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLwbZFKSzVyPUKuNVY4PjJizszN M17Hb3NCVkeHUh?=
MC-CAR NXL0UGt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLUTWM2OD1{LkKyPVUh|ryP MnvPV2FPT0WU
KM-H2 NEW5cZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJwMkmwOFMh|ryP MVfTRW5ITVJ?
ECC12 NVrRcHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGD0eGxKSzVyPUKuN|c6PCEQvF2= MmHoV2FPT0WU
HCE-T Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLRTWM2OD1{LkS0PFg{KM7:TR?= MnX2V2FPT0WU
MFM-223 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1{LkWwPFcyKM7:TR?= MmDoV2FPT0WU
SW982 NXnWfohXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjETWM2OD1{LkWxOFgh|ryP M4\ue3NCVkeHUh?=
KG-1 NGXNNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq2N2kzUUN3ME2yMlg5PzlzIN88US=> NFX1dpZUSU6JRWK=
ES4 M2DwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNwME[xNVEh|ryP NUnNW405W0GQR1XS
SCC-3 NX;tN5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv6dIFwUUN3ME2zMlExQDR6IN88US=> NUHGVYlUW0GQR1XS
RH-1 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT4TWM2OD1|LkO4O|Q5KM7:TR?= NI[wXmNUSU6JRWK=
NCI-H748 NHXhcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\xTFFKSzVyPUOuOFQzPjZizszN MnHYV2FPT0WU
HCC2218 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPUTWM2OD1|LkS2PVM4KM7:TR?= MkTCV2FPT0WU
MEG-01 NVH0fVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XiOWlEPTB;Mz61PVY5KM7:TR?= NEXieVFUSU6JRWK=
NB12 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLVTWM2OD1|LkW5PFg5KM7:TR?= MX7TRW5ITVJ?
SNB75 NY\xc3EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\MdIVVUUN3ME2zMlYxOTB|IN88US=> M37iVnNCVkeHUh?=
KMS-12-PE MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nTfGlEPTB;Mz62O|czOyEQvF2= Ml\nV2FPT0WU
SKM-1 NYjITYdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M332emlEPTB;Mz63NVM4PiEQvF2= NXfYWGpTW0GQR1XS
COLO-320-HSR NHzRR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof4TWM2OD1|Lke1OlM1KM7:TR?= MXXTRW5ITVJ?
NKM-1 MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7OXZlKSzVyPUOuO|c{PzhizszN M{PaWXNCVkeHUh?=
TE-6 Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwOUS1OlEh|ryP MnH1V2FPT0WU
D-336MG NVKxeGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn[0TWM2OD12LkCxNVY3KM7:TR?= NF\oU5RUSU6JRWK=
NCI-H1650 NFmwe2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TcGlEPTB;ND6xOVc6PyEQvF2= MUjTRW5ITVJ?
ES3 M3TKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3YXWV7UUN3ME20MlMzQDJ2IN88US=> MnOwV2FPT0WU
YT MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvxV5VKSzVyPUSuN|U1OjRizszN NVmyUVNlW0GQR1XS
ES5 NV7TcXNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwNECyOVUh|ryP MWjTRW5ITVJ?
LB647-SCLC Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRwNU[zNFgh|ryP M{ntPXNCVkeHUh?=
HAL-01 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfjTWM2OD12LkW3NFM1KM7:TR?= M361Z3NCVkeHUh?=
LP-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j6OWlEPTB;ND63NlM4OSEQvF2= NWXhfYc4W0GQR1XS
BC-1 NXzlZmdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHsOmNKSzVyPUWuNFA1PDdizszN NYfsXZpLW0GQR1XS
EB-3 MmHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvlTWM2OD13LkCzNFQyKM7:TR?= NUj6[XRtW0GQR1XS
GT3TKB M2nGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILQeIpKSzVyPUWuNVc3PjJizszN NE\DdFRUSU6JRWK=
NCI-H209 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTuZWlsUUN3ME21MlE6OzV{IN88US=> NWHNcmhpW0GQR1XS
BT-474 MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLZ[ms4UUN3ME21MlI{OTB{IN88US=> NVvEW5FYW0GQR1XS
RKO NXvqR3VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TLcWlEPTB;NT6yN|QzOiEQvF2= NI\QWYJUSU6JRWK=
SIMA NFTQeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHOV3hKSzVyPUWuN|A4PjVizszN NWn1TllQW0GQR1XS
RL NYnJcZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljyTWM2OD13LkO3OVQyKM7:TR?= MV\TRW5ITVJ?
GCIY MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zCdmlEPTB;NT60O|I{PiEQvF2= MoHtV2FPT0WU
Calu-6 M4W5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j5fWlEPTB;NT62NlIh|ryP M3;CUnNCVkeHUh?=
ALL-PO NVixU3lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTVU3pCUUN3ME21MlY{Pzl3IN88US=> NX7lRW1PW0GQR1XS
ARH-77 NGXzUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP1[2xKSzVyPUWuOlcxQDdizszN MWXTRW5ITVJ?
A4-Fuk NEDuWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\6W2lEPTB;Nj6wPFEyQCEQvF2= NY\6bJN2W0GQR1XS
NCI-H1581 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:xOnlCUUN3ME22MlI{QDR7IN88US=> NVTTUldTW0GQR1XS
HUTU-80 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPweYZKSzVyPU[uN|Y5QTdizszN MX3TRW5ITVJ?
TGW Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTZwNEW1PVMh|ryP M4f3WnNCVkeHUh?=
SK-N-FI MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HacWlEPTB;Nj60OVg2PCEQvF2= NV7IRZpxW0GQR1XS
U-266 NWe0ZZRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZwNUG5NlYh|ryP NU[5fXJwW0GQR1XS
EM-2 NF\sZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XOcWlEPTB;Nj62O|A6QSEQvF2= NYj1OYtHW0GQR1XS
NMC-G1 M{HP[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDQbWR1UUN3ME22MlcyQDl3IN88US=> MoLyV2FPT0WU
KASUMI-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzFcnVKSzVyPU[uPFQ4QDdizszN NIHxWlhUSU6JRWK=
NALM-6 NVPvcWwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrENZZrUUN3ME22Mlg3PzV2IN88US=> NXftT4YxW0GQR1XS
OCI-AML2 NUCxUotIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq3TWM2OD15LkCwN|I3KM7:TR?= M{\yc3NCVkeHUh?=
SHP-77 NY\KTmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HWWGlEPTB;Nz6yNlQ{KM7:TR?= NFzOXY9USU6JRWK=
NOMO-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjCUIpKSzVyPUeuNlQzPTRizszN NWnwTHdUW0GQR1XS
SK-N-DZ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W2R2lEPTB;Nz63NVA5QSEQvF2= MVzTRW5ITVJ?
LB1047-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[5OFRMUUN3ME23MlczOjNzIN88US=> NXSxc2c{W0GQR1XS
MZ1-PC M3LPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTdwOE[1OVgh|ryP MoO3V2FPT0WU
NB10 NFzwXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTdwOUm1OVYh|ryP MVXTRW5ITVJ?
RL95-2 M3HZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[xTWM2OD16LkGwPFQzKM7:TR?= MYDTRW5ITVJ?
OMC-1 NWDXbGlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSUWlEPTB;OD61NlE6OSEQvF2= NImzNIVUSU6JRWK=
D-283MED NIXXWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT1cFZqUUN3ME24MlkyPzF7IN88US=> NVnoR|FpW0GQR1XS
MC116 M2TONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnOW3pKSzVyPUiuPVc6PCEQvF2= NFHlOWFUSU6JRWK=
SJSA-1 M17Kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTlwMEmwPVEh|ryP MoW4V2FPT0WU
JiyoyeP-2003 NHrFSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfXXY53UUN3ME25MlI6OzF5IN88US=> NITYbJlUSU6JRWK=
IST-MEL1 NGPBXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETGOHlKSzVyPUmuO|QyQThizszN M1GwZXNCVkeHUh?=
CTV-1 M3z2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz5T2gxUUN3ME2xNE4xQTd7IN88US=> NYO2S256W0GQR1XS
NH-12 NGS3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nRXmlEPTB;MUCuNlQ{OyEQvF2= M3nzc3NCVkeHUh?=
CA46 Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnlUFN1UUN3ME2xNE4{PjFizszN MW\TRW5ITVJ?
NCI-SNU-1 M{i3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;QTWM2OD1zMD60PVY6KM7:TR?= NXfDZmxKW0GQR1XS
SCLC-21H MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojYTWM2OD1zMD62OVk3KM7:TR?= MXLTRW5ITVJ?
EC-GI-10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzibJVKSzVyPUGwMlcxOzFizszN M3jyU3NCVkeHUh?=
SR MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm2c5lvUUN3ME2xNU4xOTh3IN88US=> MYPTRW5ITVJ?
NCI-H1648 M1j6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSXpJIUUN3ME2xNU4xQTZ3IN88US=> MkXtV2FPT0WU
TGBC1TKB Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fnRWlEPTB;MUGuOFExOiEQvF2= NF3YPZJUSU6JRWK=
EW-11 NGjQcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\B[|dKSzVyPUGxMlUyQDZizszN M1u0UXNCVkeHUh?=
SK-MM-2 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hj[mlEPTB;MUGuPFA3OSEQvF2= NVL3RWR[W0GQR1XS
NCI-H524 NF7yT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFzLkm4NlIh|ryP Ml;VV2FPT0WU
NOS-1 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTF{LkCzOFUh|ryP MmftV2FPT0WU
AM-38 NUjZOZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXBTWM2OD1zMj61OlM{KM7:TR?= MmPJV2FPT0WU
A498 NEG2[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF{LkewOlkh|ryP NXS2PI02W0GQR1XS
KARPAS-422 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzaZodKSzVyPUGyMlc1QTZizszN M4TCTXNCVkeHUh?=
LU-139 M4\qS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\sTWM2OD1zMj65NFI3KM7:TR?= M2qyeHNCVkeHUh?=
COR-L88 NXHReVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e1eGlEPTB;MUKuPVM5OiEQvF2= NE\JN2VUSU6JRWK=
K5 M{izd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PGeGlEPTB;MUKuPVQ3OiEQvF2= M3fsN3NCVkeHUh?=
NB13 M2rHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfMRlFKSzVyPUGyMlk4QDNizszN NETQXZJUSU6JRWK=
MRK-nu-1 M{\pSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\TUoxSUUN3ME2xN{4yQTVizszN MYDTRW5ITVJ?
MHH-NB-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;qTWlEPTB;MUOuNlkxOiEQvF2= MkfRV2FPT0WU
KU812 M4XlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF|Lk[xNlQh|ryP MlXUV2FPT0WU
TE-12 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTtTWM2OD1zMz62PVk1KM7:TR?= M3;n[XNCVkeHUh?=
NCI-N87 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF|LkezOkDPxE1? NXL4SpdnW0GQR1XS
EB2 NIjjXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33OVGlEPTB;MUOuPFUxPSEQvF2= M37qVnNCVkeHUh?=
DB NFi4cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QVHdKSzVyPUGzMlk5QDVizszN MU\TRW5ITVJ?
697 NULr[pBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF2LkS1NVEh|ryP MlewV2FPT0WU
MSTO-211H MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrmTWM2OD1zND63OFQ5KM7:TR?= MkHCV2FPT0WU
JVM-2 NIfQNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF2Lke3N|Uh|ryP MlHaV2FPT0WU
COLO-824 NVy2cG8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7STWM2OD1zND63PVk1KM7:TR?= MlTEV2FPT0WU
BC-3 NXv1S5NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[5[WZPUUN3ME2xOU4{QThizszN MnK3V2FPT0WU
BOKU M3W1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF3Lkm2NFgh|ryP Mk\QV2FPT0WU
GOTO NHLNTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX62PHhzUUN3ME2xOk46PjF5IN88US=> Mn;QV2FPT0WU
HCC2157 NILRWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HPNWlEPTB;MUeuOFc2PSEQvF2= NYTvXIh7W0GQR1XS
LS-1034 NFq3fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rWd2lEPTB;MUeuOlgyQCEQvF2= NEPYTFFUSU6JRWK=
CAL-148 NX3zR|J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF5Lkm3PVYh|ryP M2LNcHNCVkeHUh?=
MOLT-4 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTF6LkiyNFgh|ryP M2HqOXNCVkeHUh?=
Daudi MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f1c2lEPTB;MUiuPVI{OSEQvF2= M3K4fnNCVkeHUh?=
J-RT3-T3-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33mfWlEPTB;MUmuOFA3PiEQvF2= NXPXd5I4W0GQR1XS
KMOE-2 NXLHOoxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTF7Lk[0PFIh|ryP NXnzRW9KW0GQR1XS
HL-60 NVHB[FdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOzToF1UUN3ME2yNE4yQTZ3IN88US=> NYr5SmVRW0GQR1XS
P31-FUJ MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfuXmxKSzVyPUKwMlQ4PTNizszN NYTsNYVEW0GQR1XS
IM-9 M1XndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjv[pVKSzVyPUKwMlYzOjRizszN MlL3V2FPT0WU
HDLM-2 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJyLki4NlEh|ryP MmX6V2FPT0WU
NCI-H1304 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzWTWM2OD1{MT6wN|EyKM7:TR?= NIfXVYxUSU6JRWK=
NCI-H345 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO5TWM2OD1{MT6wOlQ{KM7:TR?= NGLVdVlUSU6JRWK=
RPMI-6666 MlPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrsSVBKSzVyPUKxMlM3ODJizszN MYLTRW5ITVJ?
GR-ST NYfpWJd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe2UndKSzVyPUKxMlQyPyEQvF2= NYLLd3VZW0GQR1XS
CHP-126 M1PEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3WRWhJUUN3ME2yNU43OThzIN88US=> M4S2T3NCVkeHUh?=
EHEB M3TsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJzLk[3N|Eh|ryP MknMV2FPT0WU
CPC-N NHnENWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj4TWM2OD1{ND6wNlAyKM7:TR?= NHP4OXJUSU6JRWK=
NB1 NWXw[nRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ2Lk[5N|kh|ryP NWPTVJZiW0GQR1XS
LS-123 NGL5TXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zPTGlEPTB;MkSuPVAyOiEQvF2= MWfTRW5ITVJ?
ST486 NYr3SplrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTadXhKSzVyPUK1MlEyOTNizszN NWnQRmZKW0GQR1XS
NCI-H1963 NXnISpF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDsUXdZUUN3ME2yOk4xPjJ|IN88US=> NGjablBUSU6JRWK=
U-87-MG M4XjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLXWI1kUUN3ME2yOk44PjR2IN88US=> NGPlc5lUSU6JRWK=
COR-L279 NV3rZ2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1{Nj63PVIzKM7:TR?= NWLab|I5W0GQR1XS
LU-165 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ6LkC4OlEh|ryP MXvTRW5ITVJ?
COLO-800 NHf4TGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPuTphIUUN3ME2yPE4zQTV4IN88US=> NHHNSVNUSU6JRWK=
ETK-1 M4nXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTOTWM2OD1{OD6zOFQ3KM7:TR?= MWjTRW5ITVJ?
LNCaP-Clone-FGC Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ7LkmyPFEh|ryP NFSzOWhUSU6JRWK=
SIG-M5 NWS5NWZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fOVmlEPTB;M{CuO|k2OiEQvF2= NUXCV|Z4W0GQR1XS
NB6 NFXhXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnE[21KSzVyPUOwMlk2ODNizszN NXHUToFXW0GQR1XS
NCI-H2107 M{nMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNzLkKzN|gh|ryP MlLvV2FPT0WU
SNU-C1 M4HGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm4bnZKSzVyPUOxMlMyOjZizszN NHf1[3lUSU6JRWK=
JAR MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnTbnZrUUN3ME2zNU4{Pzl7IN88US=> NWXBTXVZW0GQR1XS
L-363 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTOOGFEUUN3ME2zNk4zOTR2IN88US=> NILYe3RUSU6JRWK=
EW-24 NIPwTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTN{LkO0O|Qh|ryP NYmwfVZ2W0GQR1XS
NB69 NV3p[IJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTN|Lk[0OVQh|ryP MmPrV2FPT0WU
EW-13 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN|Lki5Olkh|ryP MoP0V2FPT0WU
Ramos-2G6-4C10 NFTieWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3naUGlEPTB;M{SuNlk6OyEQvF2= MWnTRW5ITVJ?
TE-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRZ2k2UUN3ME2zOE41QDJ{IN88US=> NHOxSG9USU6JRWK=
L-428 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTWTWM2OD1|ND63OVM3KM7:TR?= NV7qNYZ4W0GQR1XS
KP-N-YN M3;hXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3Z2pKSzVyPUO0MlkxPTdizszN Ml;qV2FPT0WU
CGTH-W-1 NYjxd3RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn4bYc4UUN3ME2zOk46ODR6IN88US=> NFvr[GxUSU6JRWK=
K-562 NVjHWZZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPOW4tKSzVyPUO3MlA5PjRizszN MmOwV2FPT0WU
NCI-H1299 NGLUVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDRTWM2OD1|OD6xOlA{KM7:TR?= NEXlUG5USU6JRWK=
RCC10RGB NGHnNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO3U44zUUN3ME2zPE4zODh|IN88US=> NEniW41USU6JRWK=
NCI-SNU-16 MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnvTWM2OD1|OD61OlU{KM7:TR?= MWTTRW5ITVJ?
LC-2-ad MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFX4ZlRKSzVyPUO5MlQ{OzdizszN MojKV2FPT0WU
MHH-PREB-1 NIDuWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPVdXhKSzVyPUO5Mlc{QDhizszN NXz1RnRLW0GQR1XS
NCI-H64 NYD5NplkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu4bWs4UUN3ME20NE4xQTR6IN88US=> MkH5V2FPT0WU
LB996-RCC NVTnfWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj1U5lKSzVyPUSwMlg4OTZizszN NWfZfodQW0GQR1XS
DEL M4PRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{exbGlEPTB;NEGuOFQxPSEQvF2= NVLabXN7W0GQR1XS
MLMA NHzw[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRzLke1PVUh|ryP NVTU[o5wW0GQR1XS
SBC-1 NH7WdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm5eJNKUUN3ME20Nk4yQDB4IN88US=> M1f6dnNCVkeHUh?=
MPP-89 NW[5WHlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe3c3drUUN3ME20Nk42QDd3IN88US=> NWPZb2xzW0GQR1XS
MV-4-11 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37kVGlEPTB;NEKuPVA3PyEQvF2= M1;lTHNCVkeHUh?=
EoL-1- NWPzVm9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;jemlEPTB;NESuNVU3QCEQvF2= MWXTRW5ITVJ?
CW-2 NFLVOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TXPGlEPTB;NESuPFM1OiEQvF2= NXXnd5pZW0GQR1XS
HT NYLJNmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTRb4dKSzVyPUS1MlcxODdizszN M{SwWHNCVkeHUh?=
SW954 NIH1fIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTR5LkSxNlgh|ryP NWfNcHhbW0GQR1XS
A3-KAW M{\C[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fjZ2lEPTB;NEmuPFA3OSEQvF2= M1XOeXNCVkeHUh?=
TC-YIK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3pTWM2OD13MD6wN|Y{KM7:TR?= MV3TRW5ITVJ?
SW962 NEWzeHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXpW20zUUN3ME21OE45OzV5IN88US=> M2\FUnNCVkeHUh?=
KP-N-RT-BM-1 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS2dXdMUUN3ME21Ok43PjN6IN88US=> MXzTRW5ITVJ?
NCI-H1395 NX;HR41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluxTWM2OD13OD64NVczKM7:TR?= NX;pe3FUW0GQR1XS
RPMI-8402 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[4XmlEPTB;NUiuPVUzPiEQvF2= NF7jbHNUSU6JRWK=
SCH Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLnR2pJUUN3ME22NE46PjN6IN88US=> NIS5V2dUSU6JRWK=
NCI-H2196 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m3TWlEPTB;NkGuNlMyKM7:TR?= NW\MSohnW0GQR1XS
LOXIMVI NIO1SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\oRWlEPTB;NkGuPFI3PiEQvF2= M3fjTnNCVkeHUh?=
TGBC24TKB NVT2dlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;yVmlEPTB;NkKuNVQ6OSEQvF2= Ml7vV2FPT0WU
SK-MEL-2 M1XlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXBTWM2OD14Mz65PFkzKM7:TR?= MmnaV2FPT0WU
U-698-M NXi2OodtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZ6LkW2PFch|ryP NFXhbYlUSU6JRWK=
NCI-H1522 NFzoUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfjdFVKUUN3ME22PU4xODR5IN88US=> Mnv1V2FPT0WU
UACC-812 NUfaRWNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M12wXWlEPTB;NkmuOVIxQSEQvF2= NXOzSIw4W0GQR1XS
MHH-CALL-2 NVjEWHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjzfpVKSzVyPUewMlA3KM7:TR?= M3HTcXNCVkeHUh?=
NB5 NHrtbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTdyLkO0Olgh|ryP M1vhWXNCVkeHUh?=
KARPAS-299 M1vncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm3O4FwUUN3ME23NE41PDR5IN88US=> MX\TRW5ITVJ?
NCI-H1694 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDa[XMzUUN3ME23NU4xOzJizszN MY\TRW5ITVJ?
NCI-H82 NEfvXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hrc2lEPTB;N{GuPVUxPyEQvF2= M3r3cHNCVkeHUh?=
SCC-15 M3;Gdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17CTmlEPTB;N{KuN|Qh|ryP MYTTRW5ITVJ?
NCI-H1436 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTd{Lke0OVYh|ryP NX\hUYIzW0GQR1XS
ATN-1 NFjDVXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\tZmFnUUN3ME23OE42ODVizszN MoTVV2FPT0WU
RPMI-8866 MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P4N2lEPTB;N{SuO|UxQSEQvF2= NUPnUJpIW0GQR1XS
HCC1599 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3BZ|NKSzVyPUe0Mlg4OzJizszN MnLEV2FPT0WU
NCI-H1155 NFPBclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSzTWM2OD15ND65N|Y4KM7:TR?= NH3vSXhUSU6JRWK=
DOHH-2 NFfoWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL5TWM2OD15ND65OVE1KM7:TR?= NWXvU3J6W0GQR1XS
SK-NEP-1 NYjLWYdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnMelJ{UUN3ME23OU4xPzV2IN88US=> NXrTcohMW0GQR1XS
HCC1187 NH7MbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPITWM2OD15Nz62NVIzKM7:TR?= Moq4V2FPT0WU
NCI-H322M NYTmb5dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPjTWM2OD15OD6zO|A6KM7:TR?= NYn0WY5[W0GQR1XS
NCI-H526 NYX2cFVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTd6LkW4O|ch|ryP M130VHNCVkeHUh?=
NCI-H2171 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTd7LkSxN|Yh|ryP MVzTRW5ITVJ?
COLO-668 M{LJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7uTWM2OD16MT61PFg1KM7:TR?= NHfhWmdUSU6JRWK=
RS4-11 NYi5T4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGzfIZjUUN3ME24Nk4zPTB3IN88US=> M364bnNCVkeHUh?=
NCI-H716 NG\xWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTh{LkmwO|Uh|ryP M3PBdHNCVkeHUh?=
LU-134-A MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPV2lEPTB;OEOuNVM2OSEQvF2= Mkj2V2FPT0WU
RPMI-8226 M1PPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTh2LkKxNFch|ryP MWnTRW5ITVJ?
KY821 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv1OHVJUUN3ME25NU43PTVzIN88US=> MoXYV2FPT0WU
ECC4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTYWGhNUUN3ME25N{45OjZ7IN88US=> NF\oNohUSU6JRWK=
EW-3 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\zNIhNUUN3ME25OE46ODhzIN88US=> M3rQRnNCVkeHUh?=
NB7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSyRmVMUUN3ME25OU44Pzh4IN88US=> NF3OUZRUSU6JRWK=
NCI-H720 M2\ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jVcWlEPTB;OUiuOFA3OSEQvF2= MUDTRW5ITVJ?
NCI-H446 M1Xne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfIdYRGUUN3ME25PU44PTh6IN88US=> NHS2ZoVUSU6JRWK=
NCI-H889 M{XrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rmeWlEPTB;MUC0MlI1OiEQvF2= NFn5S4dUSU6JRWK=
EW-22 NEnLW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TXUWlEPTB;MUC2MlE6KM7:TR?= M3TMWnNCVkeHUh?=
BV-173 M3iwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnnTWM2OD1zMEiuO|I5KM7:TR?= NX2zNZNbW0GQR1XS
WSU-NHL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XxbmlEPTB;MUC5MlY4OSEQvF2= NXnWWnRsW0GQR1XS
MN-60 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFyOT62PUDPxE1? M2PkcHNCVkeHUh?=
DG-75 NXLiXVdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnZSJdPUUN3ME2xNVMvOzV{IN88US=> MUjTRW5ITVJ?
DMS-79 NFXL[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFzNz6zPFIh|ryP NITrfYxUSU6JRWK=
SK-MEL-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHMU2F4UUN3ME2xNVgvODB7IN88US=> NWHueY02W0GQR1XS
DMS-153 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M136b2lEPTB;MUKxMlc1PSEQvF2= MYLTRW5ITVJ?
NCI-H510A NFH0dVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnjbFZyUUN3ME2xNlcvOzJizszN Mn3JV2FPT0WU
BE-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonhTWM2OD1zM{SuNFQ1KM7:TR?= MWDTRW5ITVJ?
KP-N-YS M3nPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTF|OT63N|Yh|ryP Ml7KV2FPT0WU
SUP-T1 NGjaZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S3T2lEPTB;MUSzMlcxQCEQvF2= NX7qOoVYW0GQR1XS
EW-12 NVfWeHhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnSdZdRUUN3ME2xOFQvPjl7IN88US=> MVvTRW5ITVJ?
NB14 NWfpUlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vHXmlEPTB;MUS3MlA5OiEQvF2= NES5TlhUSU6JRWK=
MDA-MB-134-VI NIrF[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7mTWM2OD1zNEiuNlY5KM7:TR?= M4rIUnNCVkeHUh?=
NCI-H1770 MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXMdFlKSzVyPUG1Ok4zPzlizszN MVjTRW5ITVJ?
TUR NGW3dHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTZTWM2OD1zNkeuPFch|ryP NG\F[nJUSU6JRWK=
NCI-H1417 NGT3d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml70TWM2OD1zOECuN|MyKM7:TR?= NHr0[5JUSU6JRWK=
IMR-5 NEXOUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF6MT61O|Eh|ryP MVHTRW5ITVJ?
NCI-H226 NFKzSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF6OD64OlYh|ryP MVXTRW5ITVJ?
NCI-H187 M3\He2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\kTWM2OD1zOUCuNFY1KM7:TR?= Ml:1V2FPT0WU
SF539 NX;KRm51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF7Mj63Nlgh|ryP MUHTRW5ITVJ?
TALL-1 Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\EWWlEPTB;MUm4MlMxPCEQvF2= M1jLb3NCVkeHUh?=
TE-441-T NIDZbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom2TWM2OD1zOUmuO|M6KM7:TR?= NVrQ[pNmW0GQR1XS
REH MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofoTWM2OD1{M{[uOlI3KM7:TR?= NVnFXHRMW0GQR1XS
MS-1 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPDfHIyUUN3ME2yN|kvOTJzIN88US=> M2X1eXNCVkeHUh?=
THP-1 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\6d2lEPTB;Mk[0Mlc{QCEQvF2= NH33TFNUSU6JRWK=
NCI-H1838 NGS1VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ5MT60OVYh|ryP MnjnV2FPT0WU
P30-OHK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTM[5VkUUN3ME2yPFMvQDR5IN88US=> NUX5SFR5W0GQR1XS
C8166 M{Lxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnsOVd2UUN3ME2zOFUvOzN6IN88US=> MWDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID